Clinical Case of Metastatic Adrenocortical Carcinoma With Unusual Evolution: Review the Literature
Luis Cabezon-Gutierreza, c, Ana Isabel Franco-Morenob, Parham Khosravi-Shahia, Sara Custodio-Cabelloª, Maria Jose Garcia-Navarrob, Rosa Maria Martin-Diazb
Abstract
Adrenocortical carcinoma (ACC) is a rare and heterogeneous malig- nancy, with an incidence of approximately 0.72 per million cases per year leading to 0.2% of all cancer deaths in the United States. Meta- static ACC has a dismal prognosis with an overall survival of less than 1 year. We present a case of a 37-year-old man with metastatic ACC with unusual good prognosis and review the therapeutic options in the literature.
Keywords: Adrenocortical carcinoma; Mitotane; Chemotherapy
Introduction
Adrenocortical carcinoma (ACC) is a rare and heterogene- ous malignancy. Adrenal tumors are very common, affecting 3-10% of the human population, and the majority are small benign non-functional adrenocortical adenomas [1]. ACC, in contrast, is a very rare disease. The Surveillance, Epidemiol- ogy, and End Results (SEER) database provides an estimation of incidence of approximately 0.72 per million cases per year leading to 0.2% of all cancer deaths in the United States [2]. The median age at diagnosis is 46 - 55 years [3]. Historically only about 30% of these malignancies are confined to the ad- renal gland at the time of diagnosis. In these cases, an open resection performed by a specialized surgeon to achieve a state of no residual disease offers the best chance for cure [2]. Reop- eration in case of a recurrence has been suggested to improve survival, but those studies are retrospective and may suffer from a selection bias with inclusion of patients with more in-
aDepartment of Medical Oncology, Torrejon University Hospital, Madrid, Spain
bDepartment of Internal Medicine, Torrejon University Hospital, Madrid, Spain
“Corresponding Author: Luis Cabezon-Gutierrez, Department of Medical On- cology, Hospital Universitario de Torrejon, C/Mateo Inurria s/n, CP 28850, Torrejon de Ardoz, Madrid, Spain. Email: pitucgp@hotmail.com
doi: http://dx.doi.org/10.14740/wjon936w
dolent clinical presentations [4, 5].
Metastatic ACC has a dismal prognosis with an overall survival of less than 1 year [6]. The most common sites of metastases are the lung, liver, lymph nodes, and less com- monly, the bones [2]. Palliation of functioning tumors may be achieved by resection of both the primary tumor and metastatic lesions. Unresectable or widely disseminated tumors may be palliated by adrenolytic therapy with mitotane and other an- tihormonal drugs (i.e., ketoconazole), and less frequently by systemic chemotherapy, and/or radiation therapy [7]. Howev- er, 5-year survival for patients with stage IV tumors is less than 20% [8, 9]. In the present communication, we describe a case in adult metastatic ACC with unusual good evolution.
Case Report
A 37-year-old man with no past medical history of hyperten- sion or prior malignancy was admitted to the University Hos- pitals of Torrejon (Madrid, Spain) in July 2013 with worsening epigastric pain, decreased appetite, and 10 kg loss of weight over 6 months. His abdomen was mildly distended and on physical examination presented ascites. Computerized tomog- raphy (CT) (Fig. 1) revealed a huge heterogeneous adrenal tumor (13 cm in diameter) on the right side, compressing the inferior vena cava (IVC) and peritoneal carcinomatosis.
The laboratory studies did not show significant steroid hormone or catecholamine excess. A biopsy was then ob- tained from the adrenal mass. The tumor showed necrosis. The epithelioid component consisted of sheet and nests of loosely cohesive polygonal cells with clear and eosinophilic cytoplasm resembling adrenocortical cells. These cells showed highly atypical nuclei and large eosinophilic nucleoli. Im- munohistochemical stains for AE1/AE3, S-100, calcitonin, ACTH, and chromogranin were negative. The Ki-67 prolifera- tion index was 10%.
The patient was subsequently started on the EDP-mi- totane regimen consisting of etoposide at a dose of 100 mg/ m2 of body surface area administered intravenously on days 2, 3, and 4 of each cycle; doxorubicin at a dose of 40 mg/m2 given intravenously on day 1; cisplatin at a dose of 40 mg/m2 given intravenously on days 3 and 4; and oral mitotane admin- istered continuously. One cycle of the regimen was defined as a 4-week interval. The patient received a total of six cycles
of chemotherapy. Mitotane was started a minimum of 1 week before the initiation of the cytotoxic treatment, with the goal of attaining a blood level of 14 - 20 mg/L. Glucocorticoid re- placement therapy was performed from the beginning of treat- ment with mitotane.
Six months after administration of mitotane, CT scan showed a reduction in size of the adrenal mass and the perito- neal metastases (Fig. 2), with a total reduction (RECIST crite- ria) around 40%.
Subsequently, the patient was taken to the surgical oncolo- gy and had right radical adrenelectomy and total omentectomy. The final pathology report showed adrenocortical carcinoma,
0
reaching surgical margins; vascular invasion; histological changes consistent with minor changes to neoadjuvant ther- apy; round stent without significant histological alterations; and YpT3NxM1 pathological staging. Post-surgical CT scan showed complete omentectomy and right adrenalectomy. However, an adrenal tissue around 7 x 3 cm which impresses tumor was observed. Visceral, peritoneal or bone metastatic lesions are discarded (Fig. 3).
After the operation, the patient continues treatment with mitotane, requiring frequent adjustments in dosage to maintain serum levels between 14 and 20 mg/L, and is still alive without progression 2 years after diagnosis.
0
G
0
0
10 cm
O
| Drug | Study phase/n | Clinical benefit |
|---|---|---|
| Cisplatin + etoposide | II/47 | ORR: 11% |
| followed by mitotane [24] | Median OS: 10 months | |
| M/EDP [25] | II/28 | ORR: 53.5% |
| CR: two patients | ||
| PR: 13 patients | ||
| SM [26] | II/22 | ORR: 36.4% |
| M/EDP vs. SM [27] | III/304 | ORR: 23.2 vs. 9.2% |
| PFS: 5.0 vs. 2.1 months | ||
| OS: 14 vs. 12 months |
M/EDP: mitotane + etoposide, doxorubicin and cisplatin; SM: strepto- zotocin + mitotane.
Discussion
ACC management often requires a multidisciplinary approach, frequently involving a medical oncologist, an endocrine sur- geon, an endocrinologist and several other disciplines. Sur- gical resection remains the corner-stone of the treatment and represents the only curative option for patients with early stage ACC. However, around 80% of these patients will present lo- cal or distant recurrence after a complete resection [10]. With regard to recurrent or advanced disease, ACC is modestly re- sponsive to standard cytotoxic chemotherapies, although vari- ous combinations have shown clear palliative benefit. Radia- tion and ablative techniques have been utilized with variable benefit depending on the clinical scenario. The pipeline for novel drug development and testing in clinical trials has been limited. The most frequently used systemic drugs in the ad- vanced disease include mitotane, cisplatin and etoposide used alone or in combination with other agents [11].
Even if the tumor cannot be removed entirely, some clini-
cians advocate maximal debulking as a means of improving survival [12-14], although others disagree as to the survival benefit of this strategy [15, 16]. Data to support routine debulk- ing of non-resectable tumors are lacking and decision making must be individualized, taking into account the underlying tu- mor biology, rate of progression, and the histologic grade [17].
Several studies confirm the prognostic value of markers of proliferation, including mitotic rate, and Ki-67 expression (as detected by a monoclonal antibody against Ki-67, MIB1) [18, 19]. The importance of proliferative rate in prognostication was shown in an analysis of 124 patients with ACC, in whom the 5-year disease-specific survival rates for individuals with tumor mitotic rates of ≤ 5, 6 - 10, 21 - 50, and > 50 per 50 high- power fields were 63%, 50%, 25%, and 0%, respectively [18]. Malandrino et al demonstrated in the multivariate analysis like mitotane level 14 mg/L and objective response to platinum- based chemotherapy were found to be independent predictors of survival (P < 0.03 and P < 0.001). This study suggests a prognostic role for mitotane therapy and objective response to platinum-based chemotherapy [20].
Evidence for use of mitotane as the only approved drug for advanced ACC is based on retrospective series of data as opposed to any prospective, randomized controlled trials. Mi- totane is considered one of the most active agents in ACC with response rates ranging from 13% to 31% [21]. However, com- plete responses rarely occur. In terms of overall survival, four studies concluded that mitotane treatment does not increase the survival rate whereas five found an increase in the survival rate [13, 21-23].
Primary treatment with mitotane may be indicated for pa- tients who have histologically proven ACC in whom surgery is incomplete, not feasible, or contraindicated. The quality of the available literature on mitotane monotherapy is poor, and the results are highly variable. Most studies were conducted in early years without monitoring of tumor response with ad- equate imaging. It is generally accepted, though not proven, that chemotherapy plus mitotane produces better outcomes than does mitotane alone. Therefore, in the setting of exten-
| Drug | Target | Study phase/n | Clinical benefit |
|---|---|---|---|
| Sunitinib [32] | VEGF pathway | II/35 | Five patients with SD |
| Sorafenib + paclitaxel [33] | VEGF pathway + chemotherapy | II/9 | No benefit |
| Bevacizumab + capecitabina [34] | VEGF pathway + chemotherapy | II/10 | No benefit |
| Erlotinib + gemcitabina [35] | EGFR pathway + chemotherapy | II/10 | One patient with SD |
| Gefitinib [36] | EGFR pathway | II/19 | No benefit |
| Figitumumab [37] | IGF-1R pathway | II/14 | Eight patients with SD |
| Cixutumumab [38] | IGF-1R pathway | II/10 | One patient with SD |
| Cixutumumab + temsirolimus [39] | IGF-1R pathway + mTOR pathway | I/10 | Four patients with SD |
| Everolimus [40] | mTOR pathway | II/4 | No benefit |
| Imatinib [41] | c-ABL, PDGFR and c-Kit pathway | II/4 | No benefit |
| Linsitinib [31] | Dual inhibitor of IGFR and IR tyrosine kinase | III/139 | No benefit |
VEGF: vascular endothelial growth factor; EGFR: epidermal growth factor receptor; IGF-1R: insulin growth factor 1 receptor; mTOR: mammalian target of rapamycin; PDGFR: platelet-derived growth factor receptor.
sive (multiple tumor-involved organs) rapidly progressive high-grade disease, mitotane is almost always administered in combination with cytotoxic chemotherapy. A few prospective trials have explored combination regimens that contain mito- tane (Table 1) [24-27].
Although no chemotherapy regimen has been shown to improve overall survival in patients with advanced ACC, some of the more encouraging results have been with the combina- tion of EDP plus mitotane. The largest trial of advanced ACC to date, the First International Randomized trial in locally ad- vanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT), randomly assigned 304 patients with advanced ACC not amenable to radical surgery to mitotane plus either EDP or streptozotocin [27]. Rates of objective tumor response (23% versus 9%) and median progression-free survival (PFS) (5 versus 2.1 months) were both significantly better in the EDP-mitotane (EDP-M) group, although these benefits did not translate into a significantly prolonged survival (median 14.8 versus 12 months). This lack of significant difference in over- all survival, despite better PFS for EDP-M, is possibly due to the cross-over design of the study, since EDP-M was superior as a second-line treatment as well. Rates of serious adverse events did not differ significantly between treatments. The ef- ficacy of both regimens as second-line therapy was similar to their efficacy as first-line therapy. Results with other chemo- therapy drugs combined with mitotane seem to be less promis- ing [26-29].
Because of the age of our patient, low Ki-67 (< 10%), good response to chemotherapy and good performance status (0), we decided to perform debulking surgery and subsequent- ly maintaining mitotane therapy. From the date of diagnosis of the disease, it has not been objectified progression, with a PFS of 24 months, which exceeds the usual median of 5 months [27]. This difference is probably explained by the patient’s age, good performance status, Ki-67 < 10% and the possibility of debulking surgery.
A better understanding of ACC biology has provided some rationale for the development of novel agents in this disease. Unfortunately, new agents have resulted in minimal or no ac- tivity and new investigations/clinical trials need to be encour- aged to incorporate this strategy in the clinical practice (Table 2) [30-41].
A placebo-controlled phase III trial of linsitinib, an oral small molecule of both the IGF-1R and insulin receptor, in ad- vanced ACC failed to demonstrate any benefit in disease-free or overall survival [31]. However, as with cixutumumab, par- tial responses and disease stabilization (in some cases lasting for years) were seen in a small subset of patients. Although IGF-1R inhibitors cannot yet be recommended to any patient with advanced ACC, ongoing efforts to determine the genetic fingerprint that defines it will hopefully allow future selection of patients who might benefit from this approach.
The role of immune regulation in tumor progression and metastasis has been investigated and the interest in this sub- ject is tremendously increasing. As an example, blocking pro- grammed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, results in significant antitumor activity in sev- eral malignancies. Efforts should be also done to clarify the po- tential of novel immunotherapies to treat ACC and at least to in-
terrogate the expression of the PD-1 ligand on tumor cells [30].
Conclusion
The outcomes of the patient reported here with survival greater than 24 months argue for an aggressive treatment approach us- ing a multidisciplinary team to discuss treatment options in- cluding chemotherapy, surgery and mitotane when feasible.
Conflict of Interest
The authors declare no conflict of interest.
References
1. . Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004;25(2):309-340.
2. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adren- ocortical carcinoma: have we made progress? World J Surg. 2006;30(5):872-878.
3. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winches- ter DJ, Kebebew E, Sturgeon C. Adrenocortical carcino- ma in the United States: treatment utilization and prog- nostic factors. Cancer. 2008;113(11):3130-3136.
4. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(12):4551- 4564.
5. Erdogan I, Deutschbein T, Jurowich C, Kroiss M, Ronchi C, Quinkler M, Waldmann J, et al. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(1):181-191.
6. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Diele- man J, Kerstens MN, Links TP, Van de Poll-Franse LV, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49(11):2579-2586.
7. Burotto M, Tageja N, Rosenberg A, Mahalingam S, Quez- ado M, Velarde M, Edgerly M, et al. Brain metastasis in patients with adrenocortical carcinoma: a clinical series. J Clin Endocrinol Metab. 2015;100(2):331-336.
8. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bau- ersfeld J, Sanders D, et al. Molecular classification and prognostication of adrenocortical tumors by transcrip- tome profiling. Clin Cancer Res. 2009;15(2):668-676.
9. Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, et al. Integrated genomic char- acterization of adrenocortical carcinoma. Nat Genet. 2014;46(6):607-612.
10. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal corti- cal carcinoma. World J Surg. 2001;25(7):914-926.
11. Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrump D, et al. A phase II trial of combi- nation chemotherapy and surgical resection for the treat-
ment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer. 2002;94(9):2333-2343.
12. Bertagna C, Orth DN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocorti- cal tumors admitted to a single medical center (1951 to 1978). Am J Med. 1981;71(5):855-875.
13. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, et al. Clinical features of adren- ocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322(17):1195- 1201.
14. Grondal S, Cedermark B, Eriksson B, Grimelius L, Harach R, Kristoffersson A, Rastad J, et al. Adrenocorti- cal carcinoma. A retrospective study of a rare tumor with a poor prognosis. Eur J Surg Oncol. 1990;16(6):500-506.
15. Hogan TF, Gilchrist KW, Westring DW, Citrin DL. A clinical and pathological study of adrenocortical carcino- ma: therapeutic implications. Cancer. 1980;45(11):2880- 2883.
16. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA, Zerbini MC, et al. Adrenocortical carcinoma: clinical and labora- tory observations. Cancer. 2000;88(4):711-736.
17. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, Worden FP. Management of patients with adrenal cancer: recommendations of an in- ternational consensus conference. Endocr Relat Cancer. 2005;12(3):667-680.
18. Stojadinovic A, Ghossein RA, Hoos A, Nissan A, Mar- shall D, Dudas M, Cordon-Cardo C, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular charac- terization. J Clin Oncol. 2002;20(4):941-950.
19. Assie G, Antoni G, Tissier F, Caillou B, Abiven G, Gic- quel C, Leboulleux S, et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2007;92(1):148-154.
20. Malandrino P, Al Ghuzlan A, Castaing M, Young J, Cail- lou B, Travagli JP, Elias D, et al. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer. 2010;17(3):797-807.
21. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, Krans HM. Optimal treat- ment of adrenocortical carcinoma with mitotane: re- sults in a consecutive series of 96 patients. Br J Cancer. 1994;69(5):947-951.
22. Heilmann P, Wagner P, Nawroth PP, Ziegler R. [Therapy of the adrenocortical carcinoma with Lysodren (o,p’- DDD). Therapeutic management by monitoring o,p’- DDD blood levels]. Med Klin (Munich). 2001;96(7):371- 377.
23. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery. 1992;112(6):963- 970; discussion 970-961.
24. Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH, Crawford ED. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in
patients with locally advanced or metastatic adrenocorti- cal carcinoma: a Southwest Oncology Group Study. Can- cer. 2000;88(5):1159-1165.
25. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L. Mito- tane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer. 1998;83(10):2194-2200.
26. Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tib- blin S, Wilander E, et al. Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term sur- vival in its adjuvant use. Ann Oncol. 2000;11(10):1281- 1287.
27. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-2197.
28. Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, et al. Gemcitabine plus metro- nomic 5-fluorouracil or capecitabine as a second-/third- line chemotherapy in advanced adrenocortical carcino- ma: a multicenter phase II study. Endocr Relat Cancer. 2010;17(2):445-453.
29. Redlich A, Boxberger N, Strugala D, Fruhwald MC, Leuschner I, Kropf S, Bucsky P, et al. Systemic treat- ment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial. Klin Padiatr. 2012;224(6):366-371.
30. Fay AP, Elfiky A, Telo GH, Mckay RR, Kaymakcalan M, Nguyen PL, Vaidya A, et al. Adrenocortical carcinoma: the management of metastatic disease. Crit Rev Oncol Hematol. 2014;92(2):123-132.
31. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16(4):426-435.
32. Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pollinger A, Laubner K, et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open- label trial. J Clin Endocrinol Metab. 2012;97(10):3495- 3503.
33. Berruti A, Sperone P, Ferrero A, Germano A, Ardito A, Priola AM, De Francia S, et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol. 2012;166(3):451-458.
34. Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, Allolio B, et al. Bevacizumab plus capecit- abine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol. 2010;162(2):349-356.
35. Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, Strasburger C, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab. 2008;93(6):2057-2062.
36. Samnotra V, Vassilopoulou-Sellin R, Fojo AT, et al. A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). In: Annu- al meeting proceedings (post-meeting edition),25. 2007
[Abstr. 15527].
37. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adren- ocortical carcinoma. Cancer Chemother Pharmacol. 2010;65(4):765-773.
38. Carden CP, Kim ES, Jones RL, et al. Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase in- hibitor of insulin-like growthfactor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors. J Clin Oncol. 2010;28(Suppl.):15s [abstr 2530].
39. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011;17(18):6052-6060.
40. Fraenkel M, Gueorguiev M, Barak D, Salmon A, Gross- man AB, Gross DJ. Everolimus therapy for progressive adrenocortical cancer. Endocrine. 2013;44(1):187-192.
41. Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, et al. The role of imatinib me- sylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer. 2006;13(2):535-540.